echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > New Oral Alzheimer's Drug Obtains FDA Fast Track Qualification

    New Oral Alzheimer's Drug Obtains FDA Fast Track Qualification

    • Last Update: 2022-01-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Author: Sunshine

    On December 22, Vivoryon announced that the FDA has granted its oral small molecule drug varoglutamstat (PQ912, SIM0408) fast track qualification for the treatment of early Alzheimer’s disease (AD)


    Simcere Pharmaceuticals reached a $500 million cooperation with Vivoryon in June this year, and obtained the development and commercialization of two types of neurotoxic amyloid N3pE (pGlu-Abeta) in Greater China, including Varoglutamstat.


    Alzheimer's disease (AD) is the most common type of senile dementia.


    Varoglutamstat is an oral small-molecule inhibitor targeting glutaminyl peptide cyclotransferase (QPCT).


    Varoglutamstat can prevent the production of N3pE amyloid by inhibiting QPCT and its isoenzymes


    Neurotoxic amyloid N3pE can trigger AD-related pathological pathways

    Varoglutamstat's pharmacy, toxicology, main pharmacodynamics and other properties have been verified by preclinical studies


    Currently, there is no drug with the same target on the market globally


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.